Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Gains from Sales and Divestitures (2016 - 2018)

Cryo Cell International (CCEL) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $50550.0 as the latest value for Q3 2018.

  • On a quarterly basis, Gains from Sales and Divestitures rose 47.06% to $50550.0 in Q3 2018 year-over-year; TTM through Aug 2018 was $50550.0, a 47.06% increase, with the full-year FY2017 number at $83238.0, down 31.95% from a year prior.
  • Gains from Sales and Divestitures was $50550.0 for Q3 2018 at Cryo Cell International, up from $41797.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $122326.0 in Q4 2016 to a low of $5625.0 in Q1 2016.
  • A 5-year average of $44298.3 and a median of $34580.0 in 2015 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 261.86% in 2016, then tumbled 63.76% in 2017.
  • Cryo Cell International's Gains from Sales and Divestitures stood at $75409.0 in 2014, then crashed by 54.14% to $34580.0 in 2015, then surged by 253.75% to $122326.0 in 2016, then crashed by 31.95% to $83238.0 in 2017, then plummeted by 39.27% to $50550.0 in 2018.
  • Per Business Quant, the three most recent readings for CCEL's Gains from Sales and Divestitures are $50550.0 (Q3 2018), $41797.0 (Q2 2018), and $18957.0 (Q1 2018).